Therefore, our data suggest that the use of the MTAP inhibitor MTDIA in MTAP+/+ tumors would conserve the noncatalytic tumor-suppressive functions while still accumulating MTA that stimulates additional tumor suppressive functions through PRMT5 inhibition. The gene discussed is MTAP; the disease is neoplasm.